Neurocrine's drug cuts schizophrenia symptoms in mid-stage study

Neurocrine Biosciences (NBIX.O) said on Wednesday its drug helped reduce the severity of schizophrenia symptoms in a mid-stage trial, but its shares fell nearly 17% on worries whether the benefit could be replicated in larger trials.